FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma
The FDA has approved ide-cel (Abecma) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.
Source: onclive.com
Abecma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Abecma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Abecma Today - Breaking & Trending Today
Immune Engager Therapies Demonstrate Promise Following Relapse on Ide-Cel in Multiple Myeloma
Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.
Source: onclive.com
Idecabtagene Vicleucel Approaches EU Approval in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
The EMA's CHMP has recommended the approval of idecabtagene vicleucel in patients with multiple myeloma who received at least 2 prior therapies.
Source: onclive.com
Ecma: 'Four to five years is the required development period for BS VII', ET Auto
In the global trend of increasingly stringent emission norms, Euro 7, proposed for enforcement in light duty vehicles from July 2025, will set a new record. India has been following Europe for its emission regulations. In this exclusive interview, President, ECMA (an industry Body exclusively for emission control technology suppliers in India), and Head – Commercial, BASF Catalysts India, Harindranath Revanur, discusses with ETAuto’s Sumantra Bibhuti Barooah about BSVII, how easy or challenging the shift could be, and the growing scope of ECMA.
Source: indiatimes.com
Ethiopia opens up more sectors as exchange readies for launch
Ethiopia has in the last two years opened up its telecommunications and banking sectors to participation of foreign firms.
Source: theeastafrican.co.ke